Table 2.
B cell subset counts at baseline in patients who developed versus patient who did not develop flares from week 24 through week 76 in the BLISS-76, BLISS-SC and BLISS-NEA study population.
| B cell subsets | All patients | Yes | No | P value |
|---|---|---|---|---|
| BLISS-76 | ||||
| Any flare from week 24 through week 76 | ||||
| N=720 | N=553 | N=167 | ||
| CD19+CD20+ (x103/mL) | 91.5 (42.0−175.0); N=662 | 95.0 (42.3−175.0); N=504 | 81.0 (40.0−163.0); N=158 | 0.270 |
| CD19+CD20+CD27+ (x103/mL) | 14.0 (6.0−27.0); N=662 | 14.5 (6.0−27.0); N=504 | 13.0 (7.0−25.0); N=158 | 0.464 |
| CD19+CD20+CD69+ (/mL) | 2096.5 (939.3−4357.5); N=650 | 2141.0 (867.5−4422.5); N=493 | 1958.0 (1010.0−4221.5); N=157 | 0.886 |
| CD19+CD20+CD27- (x103/mL) | 75.5 (32.8−141.3); N=662 | 79.0 (33.0−144.0); N=504 | 67.5 (30.5−127.0); N=158 | 0.209 |
| CD19+CD20+CD138+ (/mL) | 791.5 (329.3−1768.0); N=656 | 832.0 (357.0−1848.0); N=499 | 549.0 (263.5−1544.5); N=157 | 0.014 |
| CD19+CD20-CD138+ (/mL) | 474.0 (212.0−1059.0); N=655 | 485.0 (212.0−1083.0); N=499 | 449.0 (211.5−1040.0); N=156 | 0.931 |
| CD19+CD20-CD27brt (/mL) | 312.0 (117.0−714.5); N=653 | 275.5 (107.0−668.3); N=496 | 456.0 (162.5−880.0); N=157 | 0.004 |
| CD19+CD27brtCD38brt (/mL) | 320.0 (115.3−722.3); N=660 | 292.0 (109.8−675.5); N=502 | 438.0 (153.5−865.3); N=158 | 0.008 |
| Severe flare from week 24 through week 76 | ||||
| N=720 | N=120 | N=600 | ||
| CD19+CD20+ (x103/mL) | 91.5 (42.0−175.0); N=662 | 91.0 (37.0−161.0); N=113 | 92.0 (43.0−175.5); N=549 | 0.463 |
| CD19+CD20+CD27+ (x103/mL) | 14.0 (6.0−27.0); N=662 | 12.0 (5.0−26.5); N=113 | 15.0 (7.0−27.0); N=549 | 0.183 |
| CD19+CD20+CD69+ (/mL) | 2096.5 (939.3−4357.5); N=650 | 2385.0 (1063.3−5261.8); N=110 | 2046.5 (864.3−4296.3); N=540 | 0.196 |
| CD19+CD20+CD27- (x103/mL) | 75.5 (32.8−141.3); N=662 | 70.0 (30.0−136.5); N=113 | 76.0 (33.0−142.0); N=549 | 0.575 |
| CD19+CD20+CD138+ (/mL) | 791.5 (329.3−1768.0); N=656 | 756.0 (258.0−1961.0); N=113 | 795.0 (342.0−1696.0); N=543 | 0.942 |
| CD19+CD20-CD138+ (/mL) | 474.0 (212.0−1059.0); N=655 | 498.0 (209.0−1100.0); N=113 | 469.5 (211.8−1061.0); N=542 | 0.813 |
| CD19+CD20-CD27brt (/mL) | 312.0 (117.0−714.5); N=653 | 274.5 (113.5−609.3); N=112 | 320.0 (119.0−743.5); N=541 | 0.480 |
| CD19+CD27brtCD38brt (/mL) | 320.0 (115.3−722.3); N=660 | 285.0 (105.0−649.0); N=113 | 334.0 (120.0−732.0); N=547 | 0.274 |
| BLISS-SC | ||||
| Any flare from week 24 through week 76 | ||||
| N=757 | N=377 | N=380 | ||
| CD19+CD20+ (x103/mL) | 107.0 (58.0−197.5); N=736 | 102.0 (53.0−189.0); N=363 | 108.0 (59.5−205.5); N=373 | 0.161 |
| CD19+CD20+CD27+ (x103/mL) | 14.0 (7.0−29.0); N=736 | 12.0 (6.0−25.0); N=363 | 17.0 (7.0−32.0); N=373 | 0.001 |
| CD19+CD20+CD69+ (/mL) | 79.0 (32.0−198.8); N=736 | 74.0 (29.0−171.0); N=363 | 85.0 (35.0−230.0); N=373 | 0.045 |
| CD19+CD20+CD27- (x103/mL) | 89.0 (44.0−167.0); N=736 | 90.0 (43.0−158.0); N=363 | 89.0 (44.5−177.0); N=373 | 0.414 |
| CD19+CD20+CD138+ (/mL) | 53.0 (20.0−131.8); N=736 | 55.0 (22.0−130.0); N=363 | 52.0 (19.0−133.5); N=373 | 0.735 |
| CD19+CD20-CD138+ (/mL) | 198.0 (67.0−501.8); N=736 | 224.0 (69.0−566.0); N=363 | 176.0 (62.5−449.5); N=373 | 0.168 |
| CD19+CD20-CD27brt (/mL) | 2000.0 (1000.0−4000.0); N=736 | 2000.0 (1000.0−4000.0); N=363 | 2000.0 (1000.0−4000.0); N=373 | 0.132 |
| CD19+CD27brtCD38brt (/mL) | 1723.5 (728.3−3887.3); N=736 | 1594.0 (630.0−3733.0); N=363 | 1795.0 (763.0−4046.0); N=373 | 0.184 |
| Severe flare from week 24 through week 76 | ||||
| N=757 | N=63 | N=694 | ||
| CD19+CD20+ (x103/mL) | 107.0 (58.0−197.5); N=736 | 70.0 (29.5−165.3); N=62 | 108.5 (60.8−200.0); N=674 | 0.002 |
| CD19+CD20+CD27+ (x103/mL) | 14.0 (7.0−29.0); N=736 | 8.5 (5.0−21.3); N=62 | 15.0 (7.0−30.0); N=674 | 0.001 |
| CD19+CD20+CD69+ (/mL) | 79.0 (32.0−198.8); N=736 | 55.0 (26.0−111.0); N=62 | 82.0 (33.0−205.0); N=674 | 0.007 |
| CD19+CD20+CD27- (x103/mL) | 89.0 (44.0−167.0); N=736 | 61.0 (23.8−146.3); N=62 | 92.0 (46.0−170.3); N=674 | 0.007 |
| CD19+CD20+CD138+ (/mL) | 53.0 (20.0−131.8); N=736 | 44.0 (16.0−100.5); N=62 | 54.5 (20.0−135.0); N=674 | 0.155 |
| CD19+CD20-CD138+ (/mL) | 198.0 (67.0−501.8); N=736 | 248.0 (65.0−611.5); N=62 | 194.5 (67.0−496.5); N=674 | 0.460 |
| CD19+CD20-CD27brt (/mL) | 2000.0 (1000.0−4000.0); N=736 | 1500.0 (750.0−3000.0); N=62 | 2000.0 (1000.0−4000.0); N=674 | 0.421 |
| CD19+CD27brtCD38brt (/mL) | 1723.5 (728.3−3887.3); N=736 | 1698.5 (649.8−3620.0); N=62 | 1723.5 (728.8−3909.3); N=674 | 0.912 |
| BLISS NEA | ||||
| Any flare from week 24 through week 76 | ||||
| N=60 | N=40 | N=20 | ||
| CD19+CD20+ (x103/mL) | 54.0 (22.0−102.0); N=51 | 54.0 (28.0−121.0); N=27 | 53.5 (17.3−90.5); N=24 | 0.503 |
| CD19+CD20+CD27+ (x103/mL) | 7.4 (3.5−10.7); N=52 | 7.2 (3.2−11.7); N=28 | 7.4 (4.4−10.7); N=24 | 0.673 |
| CD19+CD20+CD69+ (/mL) | 106.6 (45.5−182.8); N=52 | 114.4 (46.8−182.8); N=28 | 106.6 (45.0−182.4); N=24 | 0.883 |
| CD19+CD20+CD27- (x103/mL) | 40.5 (18.7−94.5); N=52 | 43.1 (25.1−99.2); N=28 | 38.9 (15.0−77.8); N=24 | 0.533 |
| CD19+CD20+CD138+ (/mL) | 100.1 (58.3−247.3); N=52 | 84.9 (50.3−457.2); N=28 | 114.1 (64.1−201.3); N=24 | 0.783 |
| CD19+CD20-CD138+ (/mL) | 301.2 (175.6−685.7); N=52 | 390.5 (179.3−708.7); N=28 | 257.2 (128.1−596.8); N=24 | 0.322 |
| CD19+CD20-CD27brt (/mL) | 970.6 (229.7−2204.8); N=52 | 1053.1 (290.2−2204.8); N=28 | 935.7 (213.4−2537.5); N=24 | 0.646 |
| CD19+CD27brtCD38brt (/mL) | 954.4 (263.2−2218.4); N=52 | 998.5 (269.7−2218.4); N=28 | 919.8 (210.4−2274.6); N=24 | 0.633 |
| Severe flare from week 24 through week 76 | ||||
| N=56 | N=4 | N=52 | ||
| CD19+CD20+ (x103/mL) | 54.0 (22.0−102.0); N=51 | 61.5 (14.3−158.3) | 54.0 (28.0−95.0); N=47 | 0.879 |
| CD19+CD20+CD27+ (x103/mL) | 7.4 (3.5−10.7); N=52 | 5.1 (3.6−59.6) | 7.5 (3.5−10.7); N=48 | 0.882 |
| CD19+CD20+CD69+ (/mL) | 106.6 (45.5−182.8); N=52 | 100.6 (50.0−139.4) | 106.6 (45.0−186.6); N=48 | 0.778 |
| CD19+CD20+CD27- (x103/mL) | 40.5 (18.7−94.5); N=52 | 57.2 (9.3−99.2) | 40.5 (19.5−85.5); N=48 | 0.728 |
| CD19+CD20+CD138+ (/mL) | 100.1 (58.3−247.3); N=52 | 143.8 (40.8−442.3) | 89.7 (58.3−247.3); N=48 | 0.753 |
| CD19+CD20-CD138+ (/mL) | 301.2 (175.6−685.7); N=52 | 173.4 (80.2−357.4) | 309.6 (185.6−701.8); N=48 | 0.121 |
| CD19+CD20-CD27brt (/mL) | 970.6 (229.7−2204.8); N=52 | 1059.9 (280.8−2322.3) | 970.6 (229.7−2204.8); N=48 | 0.960 |
| CD19+CD27brtCD38brt (/mL) | 954.4 (263.2−2218.4); N=52 | 1096.7 (296.8−2048.0) | 954.4 (263.2−2308.9); N=48 | 1.000 |
Data are presented as medians (interquartile range) of absolute counts. In case of missing values, the total number of patients with available data is indicated. P values are derived from non-parametrical Mann-Whitney U tests. Statistically significant P values are in bold.
NEA, Northeast Asia; SC, subcutaneous.